The Department of Justice (DOJ) has charged a Teva Pharmaceuticals subsidiary with allegedly conspiring to rig prices for generic drugs, making it the seventh drugmaker to be indicted as part of an ongoing probe.

The indictment accuses Teva USA of allegedly participating in three conspiracies between May 2013 and December 2015 to fix prices on various generic products in which consumers were allegedly overcharged by at least $350 million.

Israel-based Teva said it firmly rejects the allegations and will vigorously defend its U.S. subsidiary in court.